07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Pfizer, Ranbaxy cardiovascular, metabolic, genitourinary news

The companies settled most of their worldwide patent litigation for Pfizer’s cholesterol drug Lipitor atorvastatin and its hypertension and hypercholesterolemia drug Caduet amlodipine/atorvastatin. Pfizer will grant Ranbaxy rights to market generic atorvastatin in the U.S....